FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA

Clinical trials for FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA trials appear

Sign up with your email to follow new studies for FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug duo targets Tough-to-Treat kidney cancer

Disease control Ongoing

This study is testing whether combining two existing cancer drugs, nivolumab and cabozantinib, is safe and effective for people with advanced non-clear cell kidney cancer that has spread. The trial will enroll about 60 adults who have had limited prior treatment to see if the com…

Matched conditions: FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Mar 31, 2026 12:10 UTC

FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA

Get alerted when new FUMARATE HYDRATASE DEFICIENT RENAL CELL CARCINOMA trials appear

New drug duo targets Tough-to-Treat kidney cancer